Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bortezomib added to ongoing endocrine therapy in endocrine-resistant metastatic breast cancer
2006-004144-23Phase 2Completed
- Sponsor
- AZ Sint-Augustinus
- Start
- Mar 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in breast cancer (2 arms), sponsored by AZ Sint-Augustinus. Primary endpoints: Clinical benefit rate and Clinical activity decision threshold. Started Mar 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004144-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004144-23.